References
- Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54
- Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet 1997;101:355-8
- Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-6
- Pinto R, Caseiro C, Lemos M, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 2004;12:87-92
- Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005;28:1011-17
- Swiedler SJ, Beck M, Bajbouj M, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A 2005;134:144-50
- Useful information on rare diseases from an EU perspective. Available at http://ec.europa.eu/health/ph_information/documents/ev20040705_rd05_en.pdf [Last accessed 31 October 2008]
- Aymé S, Kole A, Groft S. Empowerment of patients: lessons from the rare diseases community. Lancet 2008;371:2048-51
- Drummond M, Sculpher M, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford, New York: Oxford University Press, 2005
- Schlander M. Health Technology Assessments by the National Institute for Health and Clinical Excellence. A Qualitative Study. New York, USA: Springer, 2007
- Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007;120:405-18
- Hein LK, Meikle PJ, Dean CJ, et al. Development of an assay for the detection of mucopolysaccharidosis type VI patients using dried blood-spots. Clin Chim Acta 2005;353:67-74
- Auclair D, Hopwood JJ, Brooks DA, et al. Replacement therapy in mucopolysaccharidosis type VI: advantages of early onset of therapy. Mol Genet Metab 2003;78:163-74
- Lücke T, Das AM, Hartmann H, et al. Developmental outcome in five children with Hurler syndrome after stem cell transplantation: a pilot study. Dev Med Child Neurol 2007;49:693-6
- Hoogerbrugge PM, Brouwer OF, Bordigoni P, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 1995;345:1398-402
- Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144:574-80
- Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005;115:e681-9
- Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148:533-9
- Harmatz P, Giugliani R, Schwartz IVD, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 2008;94:469-75
- MPS VI Clinical Surveillance Program. Available at http://clinicaltrials.gov/ct2/show/NCT00214773 [Last accessed 31 October 2008]
- Di Natale P, Villani GR, Parini R, et al. Molecular markers for the follow-up of enzyme replacement therapy in mucopolysaccharidosis VI disease. Biotechnol Appl Biochem 2008;49(Pt 3):219-23
- Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 2005;6:489-506
- Scarpa M, Barone R, Fiumara A, et al. Enzyme replacement therapy for mucopolysaccharidoses VI in Italy. Presented at the Annual Symposium of the Society for the study of inborn errors of metabolism, Lisbon, 2--5 Sept 2008
- Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 2007;90:171-80
- Cox-Brinkman J, Smeulders MJ, Hollak CE, et al. Restricted upper extremity range of motion in mucopolysaccharidosis type I: no response to one year of enzyme replacement therapy. J Inherit Metab Dis 2007;30:47-50
- Regulation (EC) No 141/2000. Official Journal of the European Communities 2000;43(L18):1-5
- Commission regulation (EC) No 847/2000. Official Journal of the European Communities 2000;(L103):5-8
- COMP. Report to the commission in relation to article 10 of regulation 141/2000 on orphan medicinal products. Doc Ref. EMEA/35218/2005. Available at: http://www.emea.europa.eu/pdfs/human/comp/3521805en.pdf [Last accessed 25 July 2008]
- Register of designated orphan medicinal products (25/8/08). Available at http://ec.europa.eu/enterprise/pharmaceuticals/register/orphreg.htm [Last accessed 29 August 2008]
- National Commissioning Group for Highly Specialised Services. Commissioning intentions for 2008/09. Available at: http://www.ncg.nhs.uk/documents/cp_ncg_commissioning_intentions_for_2008-09.pdf [Last accessed 25 July 2008]
- Jessop E. National service standards for care of people with LSDs. 2005. Available at: http://www.ncg.nhs.uk/documents/lsd_national_service_standards_for_care_of_people_with_lsds-010805.pdf [Last accessed 25 July 2008]
- Wraith JE, Vellodi A, Cleary MA, et al. Guidelines for the investigations and management of mucopolysaccharidosis type VI. 2006. Available at: http://www.ncg.nhs.uk/documents/lsd_guidelines_for_mucopolysaccharidosis_type_IV-210306.pdf [Last accessed 25 July 2008]
- Sozialgesetzbuch V, § 73d. Available at: http://www.gesetze-im-internet.de/sgb_5/__73d.html [Last accessed 9 January 2009]
- Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007;23:36-42
- Joppi R, Bertele V, Garattini S. Orphan drug development is progressing too slowly. Br J Clin Pharmacol 2006;61:355-60
- Culyer AJ. The rationing debate: maximising the health of the whole community. The case for. BMJ 1997;314:667-9
- Dolan P. Utilitarianism and the measurement and aggregation of quality-adjusted life years. Health Care Anal 2001;9:65-76
- Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? Q J Med 2005;98:829-36
- Schlander M. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process. J Med Ethics 2008;34:534-9
- Nord E. The trade-off between severity of illness and treatment effect in cost-value analysis of health care. Health Policy 1993;24:227-38
- Hadorn DC. Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue. JAMA 1991;265:2218-25
- McKie J, Richardson J. The rule of rescue. Soc Sci Med 2003;56:2407-19
- Dolan P, Shaw R, Tsuchiya A, et al. QALY maximisation and people's preferences: a methodological review of the literature. Health Econ 2005;14:197-208
- Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics 2005;31:164-8
- Richardson J, McKie J. Empiricism, ethics and orthodox economic theory: what is the appropriate basis for decision-making in the health sector? Soc Sci Med 2005;60:265-75
- Richardson J, Iezzi A, Sinha K, McKie J. The Relative Social-Willingness to Pay Instrument: Justification and Initial Results. Melbourne, Vic: Monash University, Centre for Health Economics. Research Paper 22, April 2008. Available at: http://arrow.monash.edu.au/vital/access/manager/Repository/monash:7512 [Last accessed 9 January 2009].
- Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med 2006;62:2091-100
- Birch S, Gafni A. Information created to evade reality (ICER) -- things we should not look to for answers. Pharmacoeconomics 2006;24:1121-31
- Media release of minister of health and ageing, Australia, May2008. Available at: http://www.health.gov.au/internet/budget/publishing.nsf/Content/E87548B32DB8C0E8CA257446002B 6CF8/$File/08_health013.pdf [Last accessed 9 January 2009]
- Alcimed. Study on orphan drugs. Part I. Paris: Alcimed, 2005. Available at: http://ec.europa.eu/enterprise/pharmaceuticals/orphanmp/doc/pricestudy/final_final_report_part_1_web.pdf [Last accessed 25 July 2008]
- DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85
- McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ 2005;331:1016-19
- Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the rule of rescue. J Med Ethics 2008;34:540-4
- Sen A. Why health equity? Health Econ 2002;11:659-66
- Mooney G, Jan S. Vertical equity: weighting outcomes? or establishing procedures? Health Policy 1997;39:79-87
- Mooney G. Vertical equity in health care resource allocation. Health Care Anal 2000;8:203-15
- Dolan P, Tsuchyia A. The elicitation of distributional judgements in the context of economic evaluation. In Jones AM, ed. The Elgar Companion to Health Economics. Cheltenham: Edward Elgar, 2006
- Sen A. Rights as goals. The Austin Lecture, April 6, 1984
- Schokkaert E. The economics of distributive justice, welfare and freedom. In: Scherer K, ed. Justice: Interdisciplinary Perspectives. Cambridge: Cambridge University Press, 1992
- Sheehan M. Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness. BMJ 2005;331:1144-5
- Nord E. Cost value analysis in health care: making sense out of QALYs. Cambridge: Cambridge University Press, 1999
- Brouwer W, van Exel J, Baker R, et al. The new myth: the social value of a QALY. Pharmacoeconomics 2008;26:1-4
- McCabe C, Tsuchiya A, Claxton K, et al. Orphan drugs revisited. QJM 2006;99:341-5
- Alcimed. Study on orphan drugs. Part II. Paris: Alcimed, 2005. Available at: http://ec.europa.eu/enterprise/pharmaceuticals/orphanmp/doc/pricestudy/final_final_report_part_2_web.pdf [Last accessed 9 January 2009]
- Hughes D. Rationing drugs for rare diseases. Pharmacoeconomics 2006;24:315-16